Skip to main content
Premium Trial:

Request an Annual Quote

Nestle Health Science Buying Prometheus Laboratories

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Prometheus Laboratories today announced an agreement to be acquired by newly formed Nestle Health Science for an undisclosed amount.

Formed in January, Nestle Health Science is a wholly owned subsidiary of Nestle and is focused on developing science-based nutritional solutions for personalized medicine. According to Luis Cantarell, president and CEO of NHS, the deal is a "strategic move into gastrointestinal diagnostics."

Joseph Limber, president and CEO of Prometheus, added that as a result of the transaction, his firm will "accelerate the development of our innovative diagnostics platforms for gastroenterology and oncology and potentially into additional important therapeutic areas."

In addition to gastroenterology and oncology, Prometheus' research pipeline will include areas of interest to NHS, such as metabolic conditions and brain health.

Based in San Diego, Prometheus was founded in 1995 and develops and commercializes pharmaceutical and diagnostic products. The firm recently received approval from the New York State Department of Health to sell its Crohn's Prognostic test, which combines six serologic markers and three genetic mutation markers and provides doctors with a personalized serologic profile for patients.

Prometheus will leverage NHS' offerings and geographical reach to expand its diagnostic and pharmaceutical business model to include nutrition, Limber said.

Goldman Sachs is Prometheus' financial advisor on the deal. Latham & Watkins is providing legal advice to Prometheus.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.